Alivus Life Sciences proposes ₹5 dividend, seeks director re-appointment at AGM

Alivus Life Sciences Limited will hold its 15th Annual General Meeting on Tuesday, September 8, 2026, to approve a final dividend of ₹5 per equity share and re-appoint key leadership. The meeting, conducted via Video Conferencing or Other Audio-Visual Means (VC/OAVM), addresses critical governance and financial resolutions for the financial year ended March 31, 2026. Shareholders are advised that the record date for dividend entitlement is September 1, 2026, with payments scheduled for release on or after September 11, 2026.

The agenda includes ordinary business items such as the adoption of audited financial statements and the declaration of dividends, alongside special business regarding cost auditor remuneration. The company has appointed Mr. Bhadrash Shah, Practicing Company Secretary, as the Scrutinizer to oversee the e-voting process in compliance with SEBI Listing Regulations. Remote e-voting facilities are available from September 4, 2026, at 9:00 a.m. IST until September 7, 2026, at 5:00 p.m. IST, ensuring broad shareholder participation.

Key Resolutions and Financial Details

The primary financial resolution involves the payment of a final dividend of ₹5 per equity share, each having a face value of ₹2. This distribution is contingent upon approval by shareholders during the AGM. The company has fixed September 1, 2026, as the cut-off date for determining eligibility for both voting rights and dividend entitlement. Dividends will be credited electronically to members' bank accounts via the National Automated Clearing House (NACH) facility.

Resolution Item	Description	Key Details
Final Dividend	Payment of final dividend for FY26	₹5 per equity share (Face Value: ₹2)
Director Re-appointment	Re-appointment of retiring director	Mr. Hiren Patel (DIN: 00145149)
Cost Auditor Remuneration	Ratification of fees for FY27 audit	₹0.50 million + taxes/expenses to Kirit Mehta & Co. LLP

Leadership and Governance Updates

Shareholders will vote on the re-appointment of Mr. Hiren Patel as a Non-Executive Director. Mr. Patel, aged 53, retires by rotation under Section 152(6) of the Companies Act, 2013, and offers himself for re-appointment. He serves as the Chairman and has been associated with the company since March 6, 2024, following the change in ownership to Nirma Limited. His expertise spans consumer goods, chemicals, cement, and healthcare industries.

Additionally, the Board seeks ratification for the remuneration payable to Kirit Mehta & Co. LLP, the Cost Auditors, for the financial year ending March 31, 2027. The approved remuneration is ₹0.50 million plus applicable taxes and reimbursement of actual travel and out-of-pocket expenses. This appointment was recommended by the Audit Committee and approved by the Board on May 14, 2026.

What the Numbers Show

The proposed dividend of ₹5 per share represents a significant return to shareholders, reflecting the company's cash generation capabilities post-acquisition by Nirma Limited. With all shares held in dematerialized form, the streamlined electronic dividend process via NACH aims to reduce transit delays and enhance investor convenience. The re-appointment of Mr. Patel signals continuity in strategic leadership, leveraging his extensive experience within the Nirma group to drive further growth in Alivus Life Sciences' portfolio.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.39%	+14.76%	+20.13%	+46.43%	+50.27%	+82.15%

Alivus Life Sciences will host an in-person investor and analyst meeting on August 12, 2026, in Mumbai. The engagement is scheduled as part of the Emkay Confluence conference and aims to provide stakeholders with direct access to company representatives through both group sessions and one-on-one discussions. This interaction offers investors a platform to discuss the company’s strategic direction and operational updates directly with management.

The disclosure was made pursuant to Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 7, 2026, regarding the upcoming event. Rudalf Corriea, Company Secretary and Compliance Officer, signed the intimation letter addressed to the Department of Corporate Services at BSE and the Listing Manager at NSE.

The meeting details are structured to facilitate comprehensive dialogue between the company and its investors. The format includes a mix of group interactions and individual meetings, allowing for broader dissemination of information as well as tailored responses to specific investor queries. The event takes place at the Emkay Confluence conference venue in Mumbai.

Date	Event Name	Mode	Location	Meeting Type
August 12, 2026	Emkay Confluence - Conference	In-Person	Mumbai	Group/One on One

The company noted that the schedule and mode of the meeting may undergo changes due to exigencies on the part of the investor, analyst, or the company itself. Investors are advised to monitor official communications for any last-minute updates regarding the timing or format of the sessions.

What This Means for Investors

The scheduled meet provides a timely opportunity for market participants to engage with Alivus Life Sciences’ leadership team. As the company continues to operate under its new identity following its rebranding from Glenmark Life Sciences Limited, such direct engagements help reinforce transparency and clarity regarding its business trajectory. The inclusion of one-on-one sessions suggests a focus on addressing specific concerns or investment theses held by institutional and high-net-worth investors attending the Emkay Confluence.